Back

Cardiovascular outcomes of oral versus injectable semaglutide: a propensity-matched real-world cohort study

28 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Diabetes and the heart: pharmacotherapy (1) Pharmacotherapy ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Jacob Hicks

Emory Healthcare, Atlanta (United States of America)

6 More presentations in this session

Presentation thumbnail
Efficacy of Semaglutide in glycemic control, weight loss, and improving lipid profile- the role of baseline vitamin D levels.
Professor R. Abo Fanne (Hadera, IL)
Abstract Slides Video
Presentation thumbnail
The association between SGLT2 inhibitors and new-onset osteoporosis in patients with type 2 diabetes: a population-based longitudinal cohort study
Doctor C. Chang (Taichung, TW)
Abstract Slides Video
Presentation thumbnail
Statin therapy for primary prevention of microvascular complications in patients with heart failure and type 2 diabetes: a target trial emulation
Miss A. Matsumoto (HK)
Abstract Slides Video
Presentation thumbnail
Parallel disease trajectories of peripheral neurovascular disease and heart failure in type 2 diabetes mellitus: a 12-year prospective follow-up
Doctor D. Andric (Novi Sad, RS)
Abstract Slides Video
Presentation thumbnail
Suboptimal cardioprotective medication prescribing in patients with diabetes and stage B heart failure
Mr M. Hussain (Dundee, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Diabetes and the heart: pharmacotherapy (1)

The Event

Event poster

ESC Congress 2026

28 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice
31 August 2025
thumbnail
Congress Presentation
Prognostic outcomes of SGLT2 inhibitors versus metformin in patients with type 2 diabetes and acute myocardial infarction
29 August 2026
thumbnail
Congress Presentation
Cardiovascular and renal outcomes of Semaglutide in patients with Type 2 Diabetes Mellitus with established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease: A Meta-Analysis
31 August 2026
thumbnail
Congress Presentation
Cardiovascular outcomes across GLP-1/GIP agonists in a large, diverse real-world cohort: the INCRETIN-CV study
29 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources